Videos

Recurrent Ovarian Cancer: Selecting Second-Line Therapy

April 27th 2018

Approaching Frontline Therapy Options for Ovarian Cancer

April 27th 2018

A Case of Platinum-Sensitive Epithelial Ovarian Cancer

April 27th 2018

A Case of Platinum-Sensitive Epithelial Ovarian Cancer

April 27th 2018

A Case of Platinum-Sensitive Epithelial Ovarian Cancer

CLL: Combination Therapies and Future Outlook

April 27th 2018

Therapeutic Approach for CLL Progression

April 27th 2018

CLL: Rationale for Ibrutinib and Chemotherapy

April 27th 2018

Treatment Options for CLL

April 27th 2018

Risk Stratifying a Case of CLL

April 27th 2018

Treating Chronic Lymphocytic Leukemia in Elderly Patients

April 27th 2018

Treating Chronic Lymphocytic Leukemia in Elderly Patients

Case 4: Maintenance Strategies in CLL

April 26th 2018

Case 4: iFCR in Untreated CLL

April 26th 2018

Case 4: iFCG in Untreated CLL

April 26th 2018

Case 4: A Young, Fit Patient With MRD-Positive CLL After Immunochemotherapy

April 26th 2018

Case 3: Therapeutic Approaches for Richter Transformation

April 26th 2018

Case 3: Progression on Ibrutinib Followed by Richter Transformation

April 26th 2018

Case 3: Response to Frontline Therapy and Toxicity Management

April 26th 2018

Case 3: Elderly Patient With CLL, Mutated TP53 and NOTCH, Unmutated IgHV

April 26th 2018

Case 2: Treatment Options: Venetoclax +/- Rituximab

April 26th 2018

Case 2: 17p-Deleted CLL Progressing on Ibrutinib Therapy

April 26th 2018

Case 1: Treatment Decision: Ibrutinib Monotherapy

April 26th 2018

Case 1: Targeted Therapy: Ibrutinib for Newly Diagnosed CLL

April 26th 2018

Case 1: Prognostic Features and Chemoimmunotherapy Treatment Options

April 26th 2018

Case 1: An Elderly Patient With Newly Diagnosed High-Risk CLL

April 26th 2018

Management of Chronic Lymphocytic Leukemia

April 26th 2018

Investigating TTFields for Treatment of Newly Diagnosed Glioblastoma

ByRachel Grossman, MD

April 25th 2018

Rachel Grossman, MD, of Tel Aviv Sourasky Medical Center, discusses the treatment landscape for patients with newly diagnosed glioblastoma. She focuses on treatments utilizing tumor treating fields, an antimitotic treatment.

HCC: Third-Line Treatments and Beyond

April 25th 2018

Managing Systemic Treatment in Liver Cancer

April 25th 2018

Therapeutic Approach for HCC Progression

April 25th 2018

Initial Therapy Options for Liver Cancer

April 25th 2018

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Denosumab Biosimilar Approved For Existing Oncology Indications

In CML, Future Directions Include TKI Sequencing Strategies and Mutational Profiles

Bianchi Highlights Personalized Therapy as the Next Frontier in Myeloma and Amyloidosis

Zabilugene Almadenorepvec Plus Chemo Shows Survival Gains in Metastatic PDAC

FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer